Skip directly to content

Is Shorter Better? Understanding the Shorter Regimen For Treating Drug-Resistant Tuberculosis

Please note this publication is outdated given recent and expected future updates to World Health Organization guidelines for drug-resistant TB treatment. All-oral regimens based on bedaquiline are now the preferred treatment option for most people with drug-resistant TB. Please see instead An Activist's Guide To Bedaquiline.

Multidrug-resistant TB (MDR-TB) is a growing problem around the world, and is difficult to treat. In 2016, the World Health Organization (WHO) recommended a shorter regimen for treating MDR-TB. Now, data from a randomized controlled trial are available. This new brief from TAG and DR-TB STAT explains what the shorter regimen is, who can receive it, and its advantages and disadvantages. 

If you want to learn even more, check out the webinar we held on the phase III trial of the shorter regimen and on the phase III trial of newer TB drug, delamanid, on this page.